Pacira BioSciences' Change in Receivables rose 121.73% to $897,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $14.6 million, marking a year-over-year increase of 294.86%. This contributed to the annual value of $7.7 million for FY2024, which is 8.23% up from last year.
Latest data reveals that Pacira BioSciences reported Change in Receivables of $897,000 as of Q3 2025, which was down 90.66% from $9.6 million recorded in Q2 2025.
In the past 5 years, Pacira BioSciences' Change in Receivables ranged from a high of $15.8 million in Q2 2021 and a low of -$18.4 million during Q3 2021.
In the last 3 years, Pacira BioSciences' Change in Receivables had a median value of $897,000 in 2025 and averaged $1.5 million.
Its Change in Receivables has fluctuated over the past 5 years, first crashed by 962.60% in 2021, then skyrocketed by 688.68% in 2023.
Quarterly analysis of 5 years shows Pacira BioSciences' Change in Receivables stood at $13.5 million in 2021, then crashed by 63.52% to $4.9 million in 2022, then surged by 74.56% to $8.6 million in 2023, then skyrocketed by 47.12% to $12.7 million in 2024, then skyrocketed by 121.73% to $897,000 in 2025.
Its Change in Receivables was $897,000 in Q3 2025, compared to $9.6 million in Q2 2025 and -$8.6 million in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value